Why Cancer Advocacy and Access to Biomarker Testing Matter

0 Views

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Published Jun 26, 2025

In this segment, Dr. Ashley Sumrall discusses why cancer patient advocacy is no longer optional—it’s essential. From rising concerns about biomarker testing access to the effects of cancer policy decisions in Washington, she shares how public engagement and oncology advocacy are shaping the future of cancer care. She also dives into how limited insurance coverage for precision oncology testing is impacting the way we approach cancer diagnosis, especially in rare and complex cases.

What you'll learn in this conversation:
▶ Why access to cancer care is still unequal, and what needs to change
▶ How a lack of biomarker access can limit cancer treatment options and affect patient outcomes
▶ The role of healthcare policy, oncology policy, and professional organizations in pushing for reform
▶ How NIH cancer research and NCI cancer research funding drives innovation in cancer treatment
▶ Why involvement at both the federal and state levels is critical for lasting impact
▶ How advocacy connects to broader conversations around natural cancer treatments and future approaches to treatment for cancer

This is a timely and vital conversation that blends policy insight with clinical experience—reminding us that behind every policy decision is a patient waiting for better care.

#canceradvocacy #biomarkertesting #precisiononcology #access2care #cancerdiagnosis #oncologynews #healthcarepolicy #nciresearch #mdnewsline #drashleysumrall #treatmentforcancer #cancerresearch #cancertreatment #oncologypolicy #naturalcancertreatments